The effect of disease severity and dopaminergic medication on the assessment of familiarity and the recollection of episodic details during recognition in nondementing idiopathic Parkinson's is uncertain. Some studies have reported familiarity as deficient in mild Parkinson's yet others have found it intact even in moderate Parkinson's. Recollection has been found to be both preserved and deficient in mild and moderate Parkinson's. The extent to which these conflicting findings are explained by disease severity or dopaminergic medication or a combination of the two is uncertain, as all studies assessed patients in a medicated state, and disease severity has not always been consistently reported.
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Twelve patients with mild Parkinson's and 11 with moderate Parkinson's (medicated Hoehn and Yahr mean: 2.1 and 3.2, respectively), completed matched versions of a yes/no recognition memory test in a medicated and unmedicated condition (termed ON and OFF, respectively). Twenty-one matched healthy volunteers also completed both memory tasks in 2 separate sessions (termed Blue and Green, respectively).
In the ON/Green condition, the moderate Parkinson's recollection performance was significantly poorer than the healthy volunteers and mild Parkinson's. By contrast, recognition memory and familiarity measures in both Parkinson's group were relatively spared. In the OFF/Blue condition, the moderate Parkinson's recollection was impaired, but only in relation to the healthy volunteer set. There were no significant differences in recollection performance between the mild and moderate Parkinson's groups. Again, recognition memory and familiarity measures in both Parkinson's group were relatively spared. Further analyses showed the moderate patients' recollection rates to be significantly poorer ON-medication compared to OFF.
These findings are discussed in relation to the staging of disease progression on medial temporal areas which separately support recollection and familiarity, and the putative effects the different classes of dopaminergic drugs may have on these areas.
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Introduction
This study investigated the effect of dopaminergic medication and disease severity on the assessment of familiarity and the recollection of episodic details during recognition in patients with nondementing idiopathic Parkinson's. These processes differ with respect to the type of information that they provide and the level of recognition confidence each typically produces. A widely held view holds that recollection is a high confidence threshold process that involves remembering specific details from episodic memory regarding a past event. By contrast, recognition based on feelings of familiarity varies continuously as a reflection of memory strength in the absence of retrieval of contextual detail (Yonelinas & Jacoby, 1995) .
There is conflicting evidence regarding the status of recollection and familiarity at different stages of Parkinson's, with only one study to date examining recollection in patients in mild and moderate stages of disease severity (Hay, Moscovitch, & Levine, 2002) . In this study, recollection was normal in the mild Parkinson's group (Hoehn & Yahr, 1967 rating severity ratings in the range of 1-2.5) but significantly declined in the moderate group (Hoehn and Yahr [HY] 3-4). Familiarity was not assessed. Three other studies have investigated the dual process view of recognition memory, sampling patients at a single disease stage. It is important to note that there was consistency between these studies in relation to their use of the remember-know paradigm and
